@article{5b486da88fcb495bb0ffa445e9906375,
title = "Quality improvement in neurology: Amyotrophic Lateral Sclerosis Quality Measures",
author = "Miller, \{Robert G.\} and Brooks, \{Benjamin Rix\} and Swain-Eng, \{Rebecca J.\} and Basner, \{Robert C.\} and Carter, \{Gregory T.\} and Patricia Casey and Cohen, \{Adam B.\} and Richard Dubinsky and Dallas Forshew and Jackson, \{Carlayne E.\} and Ed Kasarskis and Procaccini, \{Nicholas J.\} and Mohammed Sanjak and Tolin, \{Fredrik P.\}",
note = "Funding Information: Dr. Miller has received research support from the Muscular Dystrophy, and is a consultant for Cytokinetics, Neuraltus, and Asubio pharmaceuticals. Dr. Brooks has received funding and/or research grants from AB Science, Acorda, ALS Therapy Alliance, Asubio, Avanir., Biogen Idec, Bristol-Myers Squibb, Cytokinetics, GlaxoSmithKline, Knopp Bioscience, Muscular Dystrophy Association, Neu-raltus, NINDS Clinical Research Consortium, QuestCor, and Teva. Ms. Swain-Eng is a full-time employee of the American Academy of Neurology. Dr. Basner is Principal Investigator of a Muscular Dystrophy Association grant,Opto-Electronic Plethysmography (OEP): A novel non-invasive quantitative assessment of lower rib cage paradox and use of accessory muscles in patients with amyotrophic lateral sclerosis; Site Investigator and Sleep Protocol Subcommittee member of an NHLBI/NIH grant, Sleep-Disordered Breathing During Pregnancy and Risks to Cardiovascular Health; and co-investigator of the following: R01HL103676-01A1 NIH/NHLBI; Subclinical Interstitial Lung Disease in MESA; R01HL093081 NIH/NHLBI; Pulmonary Vascular Changes in Early COPD; and InterMune PIPF-016: a randomized, double-blind, placebo-controlled, phase 3 study of the efficacy and safety of Pirfenidone in patients with Idiopathic Pulmonary Fibrosis (IPF). Dr. Carter reports no disclosures. Ms. Casey is a full-time employee of Northwestern Medical Faculty Foundation, Department of Neurology. Dr. Cohen reports no disclosures. Dr. Dubinsky reports disclosures for relationships with Allergan Pharmaceuticals, NIH, and AHRQ. Ms. Forshew is a consultant for Questcor and Asubio Pharmaceuticals. Dr. Jackson has received research support from Knopp Pharmaceuticals, Biogen Idec, and Cytoki-netics. Dr. Kasarskis is a consultant for Asubio Pharmaceuticals and ATSDR. Dr. Procaccini reports no disclosures. Dr. Sanjak reports no disclosures. Dr. Tolin reports no disclosures.",
year = "2014",
month = jun,
doi = "10.3109/21678421.2013.875706",
language = "English (US)",
volume = "15",
pages = "165--168",
journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",
issn = "2167-8421",
publisher = "Taylor and Francis Ltd.",
number = "3-4",
}